Oncology PracticeAxitinib/pembrolizumab combo safe, effective against mRCCFebruary 16, 2018Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeERV expression may predict response to immune checkpoint blockade in ccRCC, other solid tumorsFebruary 9, 2018Renal Cell CarcinomaImmunotherapy
Oncology PracticeAtezolizumab-bevacizumab combo tops sunitinib as first-line therapy for RCCFebruary 7, 2018Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeRetroperitoneal lymphadenectomy did not impact OS and DFS for high risk, nonmetastatic renal cell carcinomaJanuary 29, 2018Renal Cell Carcinoma
Oncology PracticeOS similar among mRCC patients enrolled in clinical trials across different geographic regionsJanuary 17, 2018Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticePhase 1 study: Human IL-10 plus checkpoint blockade looks promising in RCC, NSCLCJanuary 11, 2018Renal Cell CarcinomaLung CancerImmunotherapy
Oncology PracticeIn Brazil, few patients get second- and third-line treatment for metastatic RCCJanuary 9, 2018Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeMutations linked to checkpoint inhibitor response in RCCJanuary 4, 2018Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeFDA approves cabozantinib for the frontline treatment of advanced RCCDecember 21, 2017Renal Cell Carcinoma
Oncology PracticeFirst-in-class glutaminase inhibitor combats anti-PD-1/PD-L1 resistanceDecember 2, 2017Immuno-oncologyMelanomaLung CancerRenal Cell Carcinoma
Oncology PracticeFDA approves sunitinib malate as adjuvant treatment for RCCNovember 17, 2017Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeCancer patients with TKI-induced hypothyroidism had better survival ratesNovember 15, 2017Patient & Survivor CareCMLGastroenterologyLeukemia, Myelodysplasia, TransplantationALLLung CancerRenal Cell Carcinoma
Oncology PracticeCheckMate 214: Updated results for RCC focus on PD-L1 expression, QOLNovember 13, 2017Renal Cell CarcinomaImmuno-oncology
Oncology PracticePerioperative blood transfusion linked to worse outcomes in renal cell carcinomaNovember 5, 2017Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeHigh EZH2 expression a marker for death risk in RCCOctober 17, 2017Renal Cell CarcinomaGenitourinary Cancer
